Skip to main content

CORRECTION article

Front. Pharmacol., 05 September 2023
Sec. Pharmacology of Anti-Cancer Drugs

Corrigendum: Bibliometric analysis of evolutionary trends and hotspots of super-enhancers in cancer

  • 1Department of Neurology, The Second Xiangya Hospital of Central South University, Changsha, China
  • 2Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Changsha, China
  • 3Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China
  • 4National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
  • 5Institute of Hospital Management, Central South University, Changsha, China
  • 6Hunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha, China
  • 7Department of Pharmacy, The Second Xiangya Hospital, Institute of Clinical Pharmacy, Central South University, Changsha, China

A Corrigendum on
Bibliometric analysis of evolutionary trends and hotspots of super-enhancers in cancer

by Tang Z-C, Qu Q, Teng X-Q, Zhuang H-H, Xu W-X and Qu J (2023). Front. Pharmacol. 14:1192855. doi: 10.3389/fphar.2023.1192855

In the published article, there was an error regarding the affiliation for author Jian Qu. Instead of “Jian Qu6,7*” it should be “Jian Qu7*”. Jian Qu’s correct affiliation is “7Department of Pharmacy, The Second Xiangya Hospital, Institute of Clinical Pharmacy, Central South University, Changsha, China” and the following affiliation is incorrect and should be removed “6Hunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha, China”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: super-enhancer, bibliometric analysis, cancer, hot spots, trends

Citation: Tang Z-C, Qu Q, Teng X-Q, Zhuang H-H, Xu W-X and Qu J (2023) Corrigendum: Bibliometric analysis of evolutionary trends and hotspots of super-enhancers in cancer. Front. Pharmacol. 14:1285522. doi: 10.3389/fphar.2023.1285522

Received: 30 August 2023; Accepted: 31 August 2023;
Published: 05 September 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Tang, Qu, Teng, Zhuang, Xu and Qu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jian Qu, qujianstanley@csu.edu.cn

These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.